Mental Health is one of the most widely talked about and major concerns among adults and children. Being locked up at home during COVID might have be good for your physical health, but the mental impact has been severe.
Parasym is one of the most widely used and clinically proven medical devices used to achieve the therapeutic benefits of stimulating the vagus nerve to battle depression, anxiety and insomnia.
So how does a little device beat the likes of depression, insomnia and anxiety?
Parasym works by stimulating the auricular branch of the vagus nerve with targeted micropulses of electrical current through a specially designed electrode that connects to the tragus of the outer ear.
With Parasym it is possible to achieve safe and effective non-invasive vagus nerve stimulation. To date, Parasym has shown significant therapeutic effects associated with vagal modulation with no serious adverse events in any clinical trials and deemed non-significant risk by the FDA.
What is the Vagus Nerve?
The vagus nerve is the longest and most complex of the 12 pairs of cranial nerves that emanate from the brain. It transmits information to or from the surface of the brain to tissues and organs elsewhere in the body. The name “vagus” comes from the Latin term for “wandering.” This is because the vagus nerve wanders from the brain into organs in the neck, chest, and abdomen. Meaning it connects to most of your major organs.
The Parasym device preferentially activates afferent rather than efferent vagal fibers, offering a therapeutic advantage over invasive Vagus Nerve Stimulation (when a device is surgically implanted to connect to your Vagus Nerve). This specific field of stimulation differentiates Parasym from others and it is both low-risk and non-invasive.
How do I use it?
All it takes is 1 hour a day. Connect the Parasym electrode to your Tragus (located on the outside of your ear) for an hour a day and see the benefits within 1 to 2 weeks, which will exponentially increase over time.
We recommend 60 minutes of use per day (split in 2 x 30min sessions). It is best to find a convenient time each day, using the treatment at the same time each day, for consistency. This can be done for 30min in the morning and then again for 30min at night. You can still walk around with the device while it is operating, but let’s not go jogging or kayaking.
The Parasym device is low risk and very easy to use with many therapeutic benefits. It is clinically proven to battle the symptoms associated with depression, anxiety and insomnia without any high risks or the use of harmful medication.
With various clinical studies proving its effectiveness and thousands of people already using it across the world why wait? Buy yours now and let us help you take back control of your mental health.
Ardell, Jeffrey L., Pradeep S. Rajendran, Heath A. Nier, Bruce H. KenKnight, and J. Andrew Armour. 2015. “Central-Peripheral Neural Network Interactions Evoked by Vagus Nerve Stimulation: Functional Consequences on Control of Cardiac Function.” American Journal of Physiology-Heart and Circulatory Physiology 309 (10): H1740–52. https://doi.org/10.1152/ajpheart.00557.2015.
Chavan, SS, VA Pavlo, and KJ Tracey. 2017. “Mechanisms and Therapeutic Relevance of Neuro-Immune Communication.” Immunity 46 (6): 927–42. https://doi.org/10.1016/j.immuni.2017.06.008.
Deuchars, Susan A., Varinder K. Lall, Jennifer Clancy, Mohd Mahadi, Aaron Murray, Lucy Peers, and Jim Deuchars. 2018. “Mechanisms Underpinning Sympathetic Nervous Activity and Its Modulation Using Transcutaneous Vagus Nerve Stimulation.” Experimental Physiology 103 (3): 326–31. https://doi.org/10.1113/EP086433.
Koopman, Frieda A., Sangeeta S. Chavan, Sanda Miljko, Simeon Grazio, Sekib Sokolovic, P. Richard Schuurman, Ashesh D. Mehta, et al. 2016. “Vagus Nerve Stimulation Inhibits Cytokine Production and Attenuates Disease Severity in Rheumatoid Arthritis.” Proceedings of the National Academy of Sciences of the United States of America 113 (29): 8284–89. https://doi.org/10.1073/pnas.1605635113.
Li, Shuyan, Benjamin J. Scherlag, Lilei Yu, Xia Sheng, Ying Zhang, Reza Ali, Yumei Dong, Muhammad Ghias, and Sunny S. Po. 2009. “Low-Level Vagosympathetic Stimulation: A Paradox and Potential New Modality for the Treatment of Focal Atrial Fibrillation.” Circulation: Arrhythmia and Electrophysiology 2 (6): 645–51. https://doi.org/10.1161/CIRCEP.109.868331.
Sha, Yong, Benjamin J. Scherlag, Lilei Yu, Xia Sheng, Warren M. Jackman, Ralph Lazzara, and Sunny S. Po. 2011. “Low-Level Right Vagal Stimulation: Anticholinergic and Antiadrenergic Effects.” Journal of Cardiovascular Electrophysiology 22 (10): 1147–53. https://doi.org/10.1111/j.1540-8167.2011.02070.x.
Sheng, Xia, Benjamin J. Scherlag, Lilei Yu, Shuyan Li, Reza Ali, Ying Zhang, Guosheng Fu, et al. 2011. “Prevention and Reversal of Atrial Fibrillation Inducibility and Autonomic Remodeling by Low-Level Vagosympathetic Nerve Stimulation.” Journal of the American College of Cardiology 57 (5): 563–71. https://doi.org/10.1016/j.jacc.2010.09.034.
Stavrakis, S., N. Tran, Z. Asad, and S. S. Po. 2017. “P2437Low Level Transcutaneous Vagus Nerve Stimulation Acutely Ameliorates Diastolic Function in Humans.” European Heart Journal 38 (suppl_1). https://doi.org/10.1093/eurheartj/ehx502.P2437.
Stavrakis, Stavros, Mary Beth Humphrey, Benjamin Scherlag, Omer Iftikhar, Purvi Parwani, Mubasher Abbas, Adrian Filiberti, et al. 2017. “Low-Level Vagus Nerve Stimulation Suppresses Post-Operative Atrial Fibrillation and Inflammation: A Randomized Study.” JACC. Clinical Electrophysiology 3 (9): 929–38. https://doi.org/10.1016/j.jacep.2017.02.019.
Stavrakis, Stavros, Mary Beth Humphrey, Benjamin J. Scherlag, Yanqing Hu, Warren M. Jackman, Hiroshi Nakagawa, Deborah Lockwood, Ralph Lazzara, and Sunny S. Po. 2015. “Low-Level Transcutaneous Electrical Vagus Nerve Stimulation Suppresses Atrial Fibrillation.” Journal of the American College of Cardiology 65 (9): 867–75. https://doi.org/10.1016/j.jacc.2014.12.026.
Stavrakis, Stavros, Julie A. Stoner, Mary Beth Humphrey, Lynsie Morris, Adrian Filiberti, Justin C. Reynolds, Khaled Elkholey, et al. 2020. “TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial.” JACC: Clinical Electrophysiology 6 (3): 282–91. https://doi.org/10.1016/j.jacep.2019.11.008.
Thayer, Julian and Richard Lane. 2008. “The role of vagal function in the risk for cardiovascular disease and mortality.” Biological Psychology, 74(2):224-42. Tran, Nicole, Zain Asad, Khaled Elkholey, Benjamin J. Scherlag, Sunny S. Po, and Stavros Stavrakis. 2019. “Autonomic Neuromodulation Acutely Ameliorates Left Ventricular Strain in Humans.” Journal of Cardiovascular Translational Research 12 (3): 221–30. https://doi.org/10.1007/s12265-018-9853-6.
Verlinden, T. J. M., K. Rijkers, G. Hoogland, and A. Herrler. 2016. “Morphology of the Human Cervical Vagus Nerve: Implications for Vagus Nerve Stimulation Treatment.” Acta Neurologica Scandinavica 133 (3): 173–82. https://doi.org/10.1111/ane.12462.
Yu, Lilei, Benjamin J. Scherlag, Shuyan Li, Xia Sheng, Zhibing Lu, Hiroshi Nakagawa, Ying Zhang, et al. 2011. “Low-Level Vagosympathetic Nerve Stimulation Inhibits Atrial Fibrillation Inducibility: Direct Evidence by Neural Recordings from Intrinsic Cardiac Ganglia.” Journal of Cardiovascular Electrophysiology 22 (4): 455–63. https://doi.org/10.1111/j.1540-8167.2010.01908.x.